Brevan Howard Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Brevan Howard Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4,099	Closed	-$241K	–	1419
2023 Q4	$241K	Buy	+4,099	New	+$230K	﹤0.01%	809

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Brevan Howard Capital Management's MRTX Position: Q1 2024 in Review

Brevan Howard Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 4,099 shares — an estimated $241K sold.

Brevan Howard Capital Management first reported a position in MRTX in Q4 2023 and held it in 1 quarter. The position peaked at $241K in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Brevan Howard Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Brevan Howard Capital Management sold 4,099 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $241K.
Brevan Howard Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
Brevan Howard Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $241K in Q4 2023.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Brevan Howard Capital Management's 13F filing for Q1 2024, filed 15 May 2024.